Adeno-associated viruses (AAVs) are icosahedral capsids comprised of 60 total copies of three viral proteins (VPs), VP1, VP2, and VP3, in an approximate 1:1:10 ratio, respectively . VP3 is the smallest of the three VPs, with VP2 containing the entire sequence of VP3 as the C-terminal sequence and VP1 containing the entirety of VP2 as its C-terminal sequence . These capsids contain single-strand (ss) DNA of approximately 4.7 kb that delivers the genetic payload to target cells. There is increasing interest in AAVs as gene therapy vectors because of their highly effective delivery mechanisms, low cytotoxicity, and minimal immunogenicity. Additionally, the variety of serotypes, each having different tropisms, provides the ability to target specific cell types and organs . Currently a handful of AAV therapy products are on the market, receiving conditional or full approval by either the US Food and Drug Administration (USFDA) or the European Medicines Agency (EMA): Luxturna® (approval date: 2017, serotype: AAV2, disease: retinal dystrophy), Zolgensma® (2019, AAV9, spinal muscular dystrophy), Hemgenix® (2022, AAV5, haemophilia B), Upstaza™ (2022, AAV2, aromatic L-amino acid decarboxylase deficiency), Elevidys (2023, AAVrh74, Duchenne muscular dystrophy), and Roctavian™ (2023, AAV5, haemophilia A).